• Earlier this week, Gilead Sciences reported that regulators in the US and Europe approved expanded first-line use of Trodelvy for unresectable locally advanced or metastatic triple-negative breast cancer, including combinations with Keytruda in PD-L1 positive disease.
• This move positions Trodelvy as a guideline-backed, first-line option across PD-L1 status in metastatic triple-negative breast cancer, broadening its potential treatment role within Gilead’s oncology portfolio.
• Now, we’ll examine how Trodelvy’s new first-line role in metastatic triple-negative breast cancer could reshape Gilead’s HIV-and-oncology-focused investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Gilead Sciences Investment Narrative Recap

To own Gilead, you generally need to believe that its HIV engine can keep funding a broader oncology push, with Trodelvy emerging as a meaningful second pillar. The new first line metastatic triple negative breast cancer approvals strengthen the near term Trodelvy catalyst but do not remove key risks around pricing pressure, HIV concentration and execution on oncology uptake, which still loom large over the story.

Among recent announcements, the FDA’s acceptance of Gilead’s filing for once weekly oral Yeztugo for HIV prevention stands out next to Trodelvy’s progress. Yeztugo reinforces how dependent Gilead’s cash flows remain on HIV, so Trodelvy’s first line move matters partly because it helps balance that exposure if oncology uptake and reimbursement unfold as hoped.

Yet behind Trodelvy’s good news, investors should also keep a close eye on mounting pricing pressure and how it could reshape Gilead’s earnings power over time...

Gilead Sciences' narrative projects $34.5 billion revenue and $10.8 billion earnings by 2029.

Uncover how Gilead Sciences' forecasts yield a $157.83 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already projected Gilead reaching about US$38.1 billion in revenue and US$12.7 billion in earnings by 2029, so if you see Trodelvy’s first line approval and heavy reliance on new launches differently, you may view that outlook as either too aggressive or just the starting point for revisiting what is possible.

Explore 6 other fair value estimates on Gilead Sciences - why the stock might be worth just $128.38!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Gilead Sciences research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.

No Opportunity In Gilead Sciences?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.